Novel Therapy Target in Metastatic Prostate Cancer
Recruiting · NCT05577689 · Observational (researchers observe without assigning treatment) · Lead sponsor: Fudan University
View the official record on ClinicalTrials.gov →Interventions studied
Tissue
What this trial is about
The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically confirmed prostate cancer
- metastatic disease confirmed by image examination
- Patients who can undergo surgery or biopsy for prostate cancer
- Able to provide informed consent
Exclusion criteria
- Patients diagnosed with other types of cancer besides prostate cancer
- Not accessible to surgery sample
- Patients fail to provide informed consent
- Other situation that researchers think are unsuitable for this study
Where it is running
1 location listed.
- Fudan University Shanghai Cancer Center - Shanghai, Shanghai Municipality, China